Skip to main content
SpringerLink
Log in

Overview of Oncology Drug Development

  • Chapter
  • First Online:
Pharmacokinetics in Drug Development

  • 1629 Accesses

Abstract

In recent years, the pharmaceutical industry has focused its efforts towards the development of novel combination targeted therapies for the treatment of cancer. In the battle against the most complex and heterogeneous disease, researchers have been increasing their understanding on cell signaling pathways and tumor biology. This knowledge supports the increasing interest in combinatorial approaches to overcome challenges such as drug resistance, or sub-optimal efficacy. The development of combination therapy faces several challenges: characterization of the synergy between the two chemical entities, definition of the appropriate doses and schedule to maximize efficacy without increasing the level of adverse events, which increased significantly its level of complexity. To address these obstacles several tools are made available. In vitro, the number of cell lines validated for pre-clinical testing and the availability of high throughput screening methods has increased significantly. The characterization of cells at a genomic and protein level have improved the predictability of effects in vivo and enabled the identification of synergistic, additive, or antagonistic effects of combination therapies. In vivo, xenograft models are frequently used to optimize combination therapies and understand mechanisms of drug resistance. Moreover, in silico approaches such as multi-scale mathematical models are gaining interest to integrate knowledge on cellular pathways, cellular environment, and tumor growth in order to optimize dosing strategies. The clinical development of combination therapies has prompted the need to reassess how clinical studies are designed in order to identify the right dose and the right schedule of administration for drugs in combination. Several strategies can be used for dose escalation in phase I combination studies but the use of pharmacokinetic properties of individual drugs and the collection of pharmacodynamics endpoints early in development has proven to be essential in optimizing combination therapies across the various phases of clinical development. Finally, an increased collaboration across the pharmaceutical industry is needed for the development of combination therapies for the successful treatment of cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • A handbook for clinical investigators conducting therapeutic clinical trials supported by CTEP, DCTD, NCI. http://ctep.cancer.gov/investigatorResources/docs/InvestigatorHandbook.pdf. Accessed Oct 2014

  • Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Press MF, Allison DE, Sliwkowski MX, Lieberman G, Kelsey SM, Fyfe G (2005) Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23:2534–2543

    Article  CAS  PubMed  Google Scholar 

  • Babb J, Rogatko A, Zacks S (1998) Cancer phase I clinical trials: efficient dose escalation with overdose control. Stat Med 17:1103–1120

    Article  CAS  PubMed  Google Scholar 

  • Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27:6041–6051

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ (2009) I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 86:97–100

    Article  CAS  PubMed  Google Scholar 

  • Berry DA, Eick SG (1995) Adaptive assignment versus balanced randomization in clinical trials: a decision analysis. Stat Med 14:231–246

    Article  CAS  PubMed  Google Scholar 

  • Burzykowski T, Buyse M, Piccart-Gebhart MJ, Sledge G, Carmichael J, Luck HJ, Mackey JR, Nabholtz JM, Paridaens R, Biganzoli L, Jassem J, Bontenbal M, Bonneterre J, Chan S, Basaran GA, Therasse P (2008) Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 26:1987–1992

    Article  CAS  PubMed  Google Scholar 

  • Buyse M, Burzykowski T, Carroll K, Michiels S, Sargent DJ, Miller LL, Elfring GL, Pignon JP, Piedbois P (2007) Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 25:5218–5224

    Article  CAS  PubMed  Google Scholar 

  • Buyse M, Burzykowski T, Michiels S, Carroll K (2008) Individual- and trial-level surrogacy in colorectal cancer. Stat Methods Med Res 17:467–475

    Article  PubMed  Google Scholar 

  • Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Janne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13:1011–1019

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cheung YK, Chappell R (2000) Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 56:1177–1182

    Article  CAS  PubMed  Google Scholar 

  • Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, Benjamin RS (2007) Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25:1753–1759

    Article  PubMed  Google Scholar 

  • Cortes JE, Kantarjian HM, Brummendorf TH, Kim DW, Turkina AG, Shen ZX, Pasquini R, Khoury HJ, Arkin S, Volkert A, Besson N, Abbas R, Wang J, Leip E, Gambacorti-Passerini C (2011) Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood 118:4567–4576

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, Cappuzzo F, Incarbone M, Roncalli M, Alloision M, Santoro A, Camidge DR, Varella-Garcia M, Doebele RC (2012) Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 18:4570–4579

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Davis W, Larionov LF (1964) Progress in chemotherapy of cancer. Bull World Health Organ 30:327–341

    CAS  PubMed  PubMed Central  Google Scholar 

  • de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154

    Article  PubMed  Google Scholar 

  • de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947

    PubMed  Google Scholar 

  • Degos L, Wang ZY (2001) All trans retinoic acid in acute promyelocytic leukemia. Oncogene 20:7140–7145

    Article  CAS  PubMed  Google Scholar 

  • DeVita VT Jr, Chu E (2008) A history of cancer chemotherapy. Cancer Res 68:8643–8653

    Article  CAS  PubMed  Google Scholar 

  • Devita VT Jr, Serpick AA, Carbone PP (1970) Combination chemotherapy in the treatment of advanced Hodgkin’s disease. Ann Intern Med 73:881–895

    Article  PubMed  Google Scholar 

  • Dieras V, Lortholary A, Laurence V, Delva R, Girre V, Livartowski A, Assadourian S, Semiond D, Pierga JY (2013) Cabazitaxel in patients with advanced solid tumours: results of a Phase I and pharmacokinetic study. Eur J Cancer 49:25–34

    Article  CAS  PubMed  Google Scholar 

  • Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Awad L, Rougier P (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047

    Article  CAS  PubMed  Google Scholar 

  • Einhorn LH (2002) Curing metastatic testicular cancer. Proc Natl Acad Sci U S A 99:4592–4595

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Einhorn LH, Donohue J (1977) Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med 87:293–298

    Article  CAS  PubMed  Google Scholar 

  • Escudier B, Eisen T, Stadler WM, Szcylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134

    Article  CAS  PubMed  Google Scholar 

  • Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, Hamid O, Infante JR, Millward M, Pavlick AC, O’Day SJ, Blackman SC, Curits CM, Lebowitz P, Ma B, Ouellet D, Kefford RF (2012) Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379:1893–1901

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Farber S, Pinkel D, Sears EM, Toch R (1956) Advances in chemotherapy of cancer in man. Adv Cancer Res 4:1–71

    Article  CAS  PubMed  Google Scholar 

  • Fisher B, Costantino JP, Wickerham DL, Cronin WM (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388

    Article  CAS  PubMed  Google Scholar 

  • Fitzgibbons PL, Bradley LA, Fatheree LA, Alsabeh R, Fulton RS, Goldsmith JD, Haas TS, Karabakhtsian RG, Loykasek PA, Marolt MJ, Shen SS, Smith AT, Swanson PE (2014) Principles of analytic validation of immunohistochemical assays: guideline from the College of American Pathologists Pathology and Laboratory Quality Center. Arch Pathol Lab Med 138:1432–1443

    Article  PubMed  Google Scholar 

  • Ghersi D, Wilcken N, Simes J, Donoghue E (2005). Taxane containing regimens for metastatic breast cancer. Cochrane Database Syst Rev CD003366

    Google Scholar 

  • Giordano SH, Temin S, Kirshner JJ, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Gonzalez-Angulo AM, Krop I, Levinson J, Lin NU, Modi S, Patt DA, Perez EA, Perlmutter J, Ramakrishna N, Winer EP (2014) Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:2078–2099

    Article  CAS  PubMed  Google Scholar 

  • Graham MA, Workman P (1992) The impact of pharmacokinetically guided dose escalation strategies in phase I clinical trials: critical evaluation and recommendations for future studies. Ann Oncol 3:339–347

    CAS  PubMed  Google Scholar 

  • Guidance for industry, investigators, and reviewers: exploratory IND studies. US Department of Health and Human Services. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm078933.pdf. Accessed Dec 2014

  • Guidance for Industry: Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, including Well- Characterized, Therapeutic, Biotechnology-Derived Products. http://www.fda.Gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071597.pdf. Accessed Jan 2015

  • Hinestrosa MC, Dickersin K, Klein P, Mayer M, Noss K, Slamon D, Sledge G, Visco FM (2007) Shaping the future of biomarker research in breast cancer to ensure clinical relevance. Nat Rev Cancer 7:309–315

    Article  CAS  PubMed  Google Scholar 

  • Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L (2009) Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 15:4220–4227

    Article  CAS  PubMed  Google Scholar 

  • Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HA, Messersmith WA (2012) Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 13:773–781

    Article  CAS  PubMed  Google Scholar 

  • Investigational New Drug Applications (INDs)—Determining Whether Human Research Studies Can Be Conducted Without an IND: U.S. Department of Health and Human Services. http://www.fda.gov/downloads/Drugs/Guidances/UCM229175.pdf. Accessed Jan 2015

  • Ivy SP, Siu LL, Garrett-Mayer E, Rubinstein L (2010) Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res 16:1726–1736

    Article  PubMed  Google Scholar 

  • Johnson JR, Williams G, Pazdur R (2003) End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21:1404–1411

    Article  PubMed  Google Scholar 

  • Johnson DH, Schiller JH, Bunn PA Jr (2014) Recent clinical advances in lung cancer management. J Clin Oncol 32:973–982

    Article  CAS  PubMed  Google Scholar 

  • Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan T, Koczywas M, Loo BW, Merritt RE, Moran CA, Niell HB, O’Malley J, Patel JD, Ready N, Rudin CM, Williams CC, Gregory K, Hughes M (2013) Small cell lung cancer. J Natl Compr Canc Netw 11:78–98

    CAS  PubMed  PubMed Central  Google Scholar 

  • Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK (2011) The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 1:44–53

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, Jacobson F, Lutzker SG, Burris HA (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28:2698–2704

    Article  CAS  PubMed  Google Scholar 

  • Kummar S, Rubinstein L, Kinders R, Parchment RE, Gutierrez ME, Murgo AJ, Ji J, Mroczkowski B, Pickeral OK, Simpson M, Hollingshead M, Yang SX, Helman L, Wiltrout R, Collins J, Tomaszewski JE, Doroshow JH (2008) Phase 0 clinical trials: conceptions and misconceptions. Cancer J 14:133–137

    Article  PubMed  Google Scholar 

  • Kurzrock R, Sherman SI, Ball DW, Forastiere AA, Cohen RB, Mehra R, Pfister DG, Cohen EE, Janisch L, Nauling F, Hong DS, Ng CS, Ye L, Gagel RF, Frye J, Muller T, Ratain MJ, Salgia R (2011) Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 29:2660–2666

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Le Tourneau C, Lee JJ, Siu LL (2009) Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 101:708–720

    Article  PubMed  PubMed Central  Google Scholar 

  • Lee JJ, Feng L (2005) Randomized phase II designs in cancer clinical trials: current status and future directions. J Clin Oncol 23:4450–4457

    Article  PubMed  Google Scholar 

  • Li MC, Whitmore WF Jr, Golbey R, Grabstald H (1960) Effects of combined drug therapy on metastatic cancer of the testis. JAMA 174:1291–1299

    Article  CAS  PubMed  Google Scholar 

  • Liu P, Moon J, LeBlanc M (2006) Phase II selection designs. In: Crowley J, Ankerst D (eds) Handbook of statistics in clinical oncology. Chapman and Hall/CRC, Boca Raton, pp 155–164

    Google Scholar 

  • Liu SV, Miller VA, Lobbezoo MW, Giaccone G (2014) Genomics-based early-phase clinical trials in oncology: recommendations from the task force on methodology for the Development of Innovative Cancer Therapies. Eur J Cancer 50:2747–2751

    Article  PubMed  Google Scholar 

  • Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711

    Article  PubMed  Google Scholar 

  • Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, Buzenet G, Koehler E, Sosman JA, Schwartz LH, Gultekin DH, Koutcher JA, Donnelly EF, Andal R, Dancy I, Spriggs DR, Tew WP (2010) Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. J Clin Oncol 28:207–214

    Article  CAS  PubMed  Google Scholar 

  • Malik L (2014) Immunotherapy for bladder cancer: changing the landscape. Cancer Clin Oncol 3:36–42

    Google Scholar 

  • Mauguen A, Pignon JP, Burdett S, Domerg C, Fisher D, Paulus R, Mandrekar SJ, Belani CP, Shepherd FA, Eisen T, Pang H, Collette L, Sause WT, Dahlberg SE, Crawford J, O’Brien M, Schild SE, Parmar M, Tierney JF, Le Pechoux C, Michiels S (2013) Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients’ data. Lancet Oncol 14:619–626

    Article  PubMed  PubMed Central  Google Scholar 

  • Meany H, Balis FM, Aikin A, Whitcomb P, Murphy RF, Steinberg SM, Widemann BC, Fox E (2010) Pediatric phase I trial design using maximum target inhibition as the primary endpoint. J Natl Cancer Inst 102:909–912

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Middleman E, Luce J, Frei E 3rd (1971) Clinical trials with adriamycin. Cancer 28:844–850

    Article  CAS  PubMed  Google Scholar 

  • Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214

    Article  CAS  PubMed  Google Scholar 

  • Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124

    Article  CAS  PubMed  Google Scholar 

  • Mross K, Frost A, Steinbild S, Hedbom S, Buchert M, Fasol U, Unger C, Kratzschmar J, Heinig R, Boix O, Christensen O (2012) A phase I dose- escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 18:2658–2667

    Article  CAS  PubMed  Google Scholar 

  • Negrier S, Bushmakin AG, Cappelleri JC, Korytowsky B, Sandin R, Charbonneau C, Michaelson MD, Figlin RA, Motzer RJ (2014) Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma. Eur J Cancer 50:1766–1771

    Article  CAS  PubMed  Google Scholar 

  • Oba K, Paoletti X, Alberts S, Bang YJ, Benedetti J, Bleiberg H, Catalano P, Lordick F, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sasako M, Sakamoto J, Sargent D, Shitara K, Cutsem EV, Buyse M, Burzykowski T (2013) Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst 105:1600–1607

    Article  PubMed  PubMed Central  Google Scholar 

  • O’Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, Orlowski RZ (2009) A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 15:7085–7091

    Article  PubMed  PubMed Central  Google Scholar 

  • Omura GA (2003) Modified Fibonacci search. J Clin Oncol 21:3177

    Article  PubMed  Google Scholar 

  • O’Quigley J, Pepe M, Fisher L (1990) Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics 46:33–48

    Article  PubMed  Google Scholar 

  • Paoletti X, Baron B, Schoffski P, Fumoleau P, Lacomb D, Marreaud S, Sylvester R (2006) Using the continual reassessment method: lessons learned from an EORTC phase I dose finding study. Eur J Cancer 42:1362–1368

    Article  PubMed  Google Scholar 

  • Pazdur R (2008) Endpoints for assessing drug activity in clinical trials. Oncologist 13(Suppl 2):19–21

    Article  PubMed  Google Scholar 

  • Penel N, Isambert N, Leblond P, Ferte C, Duhamel A, Bonneterre J (2009) “Classical 3 + 3 design” versus “accelerated titration designs”: analysis of 270 phase 1 trials investigating anti-cancer agents. Invest New Drugs 27:552–556

    Article  PubMed  Google Scholar 

  • Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, Winget M, Yasui Y (2001) Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 93:1054–1061

    Article  CAS  PubMed  Google Scholar 

  • Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, Suresh AS, Thomas A, Tjulandin S, Zhang K, Murugappann S, Sidhu R (2014) Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 15:569–579

    Article  CAS  PubMed  Google Scholar 

  • Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC (2002) Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100:3063–3067

    Article  CAS  PubMed  Google Scholar 

  • Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J, Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N, McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M, Zaki MH, Jacques C, Anderson KC (2013) Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood 121:1961–1967

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, Wolter P, Long GV, Flaherty K, Nathan P, Ribas A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM, Schadendorf D (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372:30–39

    Article  PubMed  Google Scholar 

  • Rogatko A, Schoeneck D, Jonas W, Tighiouart M, Khuri FR, Porter A (2007) Translation of innovative designs into phase I trials. J Clin Oncol 25:4982–4986

    Article  PubMed  Google Scholar 

  • Rosenberg B, Vancamp L, Krigas T (1965) Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode. Nature 205:698–699

    Article  CAS  PubMed  Google Scholar 

  • Rosner GL, Stadler W, Ratain MJ (2002) Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol 20:4478–4484

    Article  CAS  PubMed  Google Scholar 

  • Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G (2005) Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 23:5474–5483

    Article  CAS  PubMed  Google Scholar 

  • Scher HI, Heller G (2002) Picking the winners in a sea of plenty. Clin Cancer Res 8:400–404

    PubMed  Google Scholar 

  • Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL (2010) Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet 375:1437–1446

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Simon R, Wittes RE, Ellenberg SS (1985) Randomized phase II clinical trials. Cancer Treat Rep 69:1375–1381

    CAS  PubMed  Google Scholar 

  • Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89:1138–1147

    Article  CAS  PubMed  Google Scholar 

  • Skolnik JM, Barrett JS, Jayaraman B, Patel D, Adamson PC (2008) Shortening the timeline of pediatric phase I trials: the rolling six design. J Clin Oncol 26:190–195

    Article  PubMed  Google Scholar 

  • Smalley RV, Carpenter J, Bartolucci A, Vogel C, Krauss S (1977) A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone (CMFVP) in patients with metastatic breast cancer: a Southeastern Cancer Study Group project. Cancer 40:625–632

    Article  CAS  PubMed  Google Scholar 

  • Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarba JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061–1068

    Article  CAS  PubMed  Google Scholar 

  • Storer BE (1989) Design and analysis of phase I clinical trials. Biometrics 45:925–937

    Article  CAS  PubMed  Google Scholar 

  • Storer BE (2001) An evaluation of phase I clinical trial designs in the continuous dose-response setting. Stat Med 20:2399–2408

    Article  CAS  PubMed  Google Scholar 

  • Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H, Ishikawa Y (2012) RET, ROS1 and ALK fusions in lung cancer. Nat Med 18:378–381

    Article  CAS  PubMed  Google Scholar 

  • Thall PF (2008) A review of phase 2–3 clinical trial designs. Lifetime Data Anal 14:37–53

    Article  PubMed  Google Scholar 

  • Thall PF, Millikan RE, Mueller P, Lee SJ (2003) Dose-finding with two agents in Phase I oncology trials. Biometrics 59:487–496

    Article  PubMed  Google Scholar 

  • The U. S. Food and Drug Administration: Crizotinib. http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm376058.htm. Accessed Oct 2014

  • Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Article  CAS  PubMed  Google Scholar 

  • Twombly R (2006) Slow start to phase 0 as researchers debate value. J Natl Cancer Inst 98:804–806

    Article  PubMed  Google Scholar 

  • Von Hoff D, Nieves J, Vocila L, Weitman S, Cvitkovic E (2007) The complete phase Ib clinical trial: a method to accelerate new agent development. J Clin Oncol 25:2562

    Google Scholar 

  • Wells SA Jr, Gosnell JE, Gagel RF, Moley J, Pfister D, Sosa JA, Skinner M, Krebs A, Vasselli J, Schlumberger M (2010) Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 28:767–772

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Williet N, Sandborn WJ, Peyrin-Biroulet L (2014) Patient-reported outcomes as primary end points in clinical trials of inflammatory bowel disease. Clin Gastroenterol Hepatol 12:1246–1256.e6

    Article  PubMed  Google Scholar 

  • Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, Plummer R (2010) Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 28:3965–3972

    Article  CAS  PubMed  Google Scholar 

  • Yin G, Li Y, Ji Y (2006) Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios. Biometrics 62:777–784

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Capital Region Cancer Centre, The Canberra Hospital, Garran, ACT, 2605, Australia

    Laeeq Malik

  2. Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, 7979 Wurzbach Road, San Antonio, TX, 78229, USA

    Steven Weitman M.D., Ph.D.

Authors
  1. Laeeq Malik
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven Weitman M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven Weitman M.D., Ph.D. .

Editor information

Editors and Affiliations

  1. Pharmacokinetics/Modeling/Simulation 2N.184 Astellas, Global Clinical Pharmacology and Exploratory Development, Northbrook, Illinois, USA

    Peter L. Bonate

  2. Oncology Clinical Pharmacology Novartis, East Hanover, New Jersey, USA

    Danny R. Howard

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Malik, L., Weitman, S. (2016). Overview of Oncology Drug Development. In: Bonate, P., Howard, D. (eds) Pharmacokinetics in Drug Development. Springer, Cham. https://doi.org/10.1007/978-3-319-39053-6_1

Download citation

Publish with us

Policies and ethics

Search

Navigation